# Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA

> **NCT03307941** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Jules Bordet Institute**

## Conditions studied

- Adenocarcinoma of the Esophagus
- Adenocarcinoma of the Gastroesophageal Junction
- Squamous Cell Carcinoma of the Esophagus

## Interventions

- **DRUG:** Monalizumab
- **DRUG:** Oxaliplatin
- **DRUG:** 5-Fluorouracil
- **RADIATION:** Metabolic
- **OTHER:** Metabolic
- **PROCEDURE:** Surgery

## Key facts

- **NCT ID:** NCT03307941
- **Lead sponsor:** Jules Bordet Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-07-20
- **Primary completion:** 2017-12-11
- **Final completion:** 2017-12-11
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Suspended collaboration with the company providing the study drug
- **Last updated:** 2017-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03307941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03307941, "Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03307941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*